Heteroscodra maculata – common name: Togo starburst tarantula. Credit: Bastian Rast

Epilepsy cure from a tarantula? A creepy but brilliant solution

Embargoed until: Publicly released:

For the first time, tarantula venom has been used to uncover a potential treatment for a devastating form of genetic epilepsy.

Journal/conference: Proceedings of the National Academy of Sciences (PNAS)

DOI: 10.1073/pnas.1804764115

Organisation/s: Florey Institute of Neuroscience and Mental Health, Institute for Molecular Bioscience, The University of Queensland

Funder: This work was supported by Citizen’s United for Research in Epilepsy Pediatrics Award 353711, Australian National Health and Medical Research Council Program Grant 10915693 (to S.P. and C.A.R.), Principal Research Fellowships (to S.P. and G.F.K.), an Australian Research Council Discovery Early Career Researcher Award Fellowship (to E.A.B.U.), a Dowd Foundation Research Fellowship (to C.A.R.), and by the GINOP-2.3.2-15-2016-00044 Project cofinanced by the European Union and the European Regional Development Fund (G.P.). The Florey Institute of Neuroscience and Mental Health is supported by infrastructure funds from the Department of Health, State Government of Victoria.

Media Release

From: Florey Institute of Neuroscience and Mental Health

Key highlights:

  • Dravet syndrome is a catastrophic infant epilepsy that results in delayed mental and behavioural development, with higher risk of early death
  • Dravet syndrome is caused when one of two copies of the SCN1A gene mutates and produces a protein that doesn’t work, leaving the patient with half the normal amount of functional protein.
  • Scientists surmised that one way to treat this disorder might be to find a drug that makes the reduced amount of healthy protein work harder.
  • The Florey’s Prof Steven Petrou, working with Queensland collaborator Prof Glenn King, realised that the venom of the West African tarantula (Heteroscodra maculata) could provide the vital breakthrough
  • The tarantula venom contained a small peptide, called Hm1a, which the researchers showed hyper-stimulates the protein that is affected in Dravet patients.
  • In a mouse model of Dravet syndrome, the spider peptide recovered activity of neurons to normal levels, which stopped seizures and prevented early mortality
  • The tarantula peptide is now a candidate for precision therapy in Dravet patients

Dravet syndrome is a catastrophic epilepsy affecting young children before their first birthday. Children live with a range of very serious symptoms including intellectual disabilities and multiple daily seizures. The disease can result in early death.

Now, using a key ingredient isolated from venomous tarantula venom, scientists from the Florey Institute of Neuroscience and Mental Health, and the Institute for Molecular Bioscience at the University of Queensland, have discovered an effective treatment for Dravet syndrome.

Dravet syndrome is caused by a mutation in a gene that produces a protein that is critical for calming electrical activity in the brain.

Patients with Dravet syndrome only have half the normal amount of this protein, meaning the brain is overactive, which results in seizures and the other features of Dravet syndrome.

“We reasoned that if we could just make the remaining protein work harder, it would effectively pick up the slack – much like a cyclist on a tandem bicycle can help her exhausted passenger by pedalling harder to maintain speed,” says Professor Steven Petrou, researcher and Director of the Florey Institute of Neuroscience and Mental Health.

Before treatment, young Dravet mice displayed reduced activity in a specific type of brain cell whose job it is to reduce overall brain activity.

“After applying the compound from the spider venom to nerve cells from the brains of Dravet mice we saw their activity immediately return to normal. Infusion into the brains of the Dravet mice not only restored normal brain function within minutes but over three days, we noted a dramatic reduction in seizures in the mice and increased survival. Every single untreated mouse died.”

The team’s results show that it may be possible to treat this previously intractable epilepsy by directly targeting the faulty gene.

The scientists are hopeful that the remaining technical challenges can be overcome, offering new hope to Dravet families.
The results were published in the Proceedings of the National Academy of Sciences of the United States of America and are publicly accessible: http://www.pnas.org/content/early/2018/08/02/1804764115


News for:



  • The Togo starburst tarantula
    The Togo starburst tarantula

    Heteroscodra maculata, commonly called the Togo starburst tarantula, produces a venom that could form the basis of a new treatment for the severe childhood epilepsy, Dravet syndrome.

    File size: 966.9 KB

    Attribution: Bastian Rast

    Permission category: © - Only use with this story

    Last modified: 06 Aug 2018 10:25am

    NOTE: High resolution files can only be downloaded here by registered journalists who are logged in.

Show less
Show more

Media contact details for this story are only visible to registered journalists.